Coeptis Therapeutics to Acquire Rights to CAR-T Technologies from University of Pittsburgh.

MANews-(C)2009-2022

Pennsylvania, US-based biopharmaceutical company Coeptis Therapeutics, Inc. (OTC: COEP) has entered into an exclusive option agreement with the University of Pittsburgh for the rights to three chimeric antigen receptor T cell (CAR-T) technologies, the company said.

Terms of the deal were not disclosed.

The technologies offer the potential to address a range of hematologic and solid tumors. Among the initial cancer indications under development are pre-clinical programmes targeting breast cancer and ovarian cancer.

The exclusive option agreement involves the intellectual property rights to three technologies jointly developed in the laboratories of Jason Lohmueller, Ph.D., Assistant Professor of Immunology; Alexander Deiters, Ph.D., Professor of Chemistry; and Olivera Finn, Ph.D., Professor of Immunology.

Per the option agreement, Coeptis paid the...

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT